ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 110 filers reported holding ERASCA INC in Q3 2023. The put-call ratio across all filers is 1.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,070 | -95.9% | 2,066 | -94.3% | 0.00% | – |
Q2 2023 | $100,467 | +911.8% | 36,401 | +1003.4% | 0.00% | – |
Q1 2023 | $9,930 | -98.2% | 3,299 | -97.4% | 0.00% | – |
Q4 2022 | $550,628 | -14.8% | 127,756 | +54.4% | 0.00% | – |
Q3 2022 | $646,000 | +1438.1% | 82,764 | +1005.6% | 0.00% | – |
Q2 2022 | $42,000 | -28.8% | 7,486 | +9.0% | 0.00% | – |
Q1 2022 | $59,000 | -60.4% | 6,867 | -28.3% | 0.00% | – |
Q4 2021 | $149,000 | +198.0% | 9,581 | +306.5% | 0.00% | – |
Q3 2021 | $50,000 | – | 2,357 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 11,055,554 | $21,779,441 | 14.15% |
EDBI Pte Ltd | 888,888 | $1,751,109 | 1.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,926,000 | $3,794,220 | 1.28% |
Cormorant Asset Management, LP | 10,813,246 | $21,302,095 | 1.24% |
AH Equity Partners LSV II, L.L.C. | 312,500 | $615,625 | 0.64% |
Artal Group S.A. | 4,721,194 | $9,301 | 0.40% |
PFM Health Sciences, LP | 3,930,633 | $7,743,347 | 0.36% |
ARMISTICE CAPITAL, LLC | 8,356,000 | $16,461,320 | 0.25% |
SANDERS MORRIS HARRIS LLC | 425,297 | $816,569 | 0.17% |
Prosight Management, LP | 264,710 | $521,479 | 0.16% |